+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Other Building Blocks 892128-60-8
892128-60-8,MFCD25976631
Catalog No.:AA00GU1C

892128-60-8 | Ly2334737

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
≥95%
in stock  
$38.00   $26.00
- +
5mg
≥95%
in stock  
$138.00   $96.00
- +
10mg
≥95%
in stock  
$256.00   $179.00
- +
25mg
≥95%
in stock  
$548.00   $383.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA00GU1C
Chemical Name:
Ly2334737
CAS Number:
892128-60-8
Molecular Formula:
C17H25F2N3O5
Molecular Weight:
389.3943
MDL Number:
MFCD25976631
SMILES:
CCCC(C(=O)Nc1ccn(c(=O)n1)[C@@H]1O[C@@H]([C@H](C1(F)F)O)CO)CCC
Properties
Computed Properties
 
Complexity:
620  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
3  
Heavy Atom Count:
27  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
3  
Rotatable Bond Count:
8  
XLogP3:
1.7  

Downstream Synthesis Route

[1]CurrentPatentAssignee:ELILILLY&CO-WO2006/65525,2006,A1Locationinpatent:Page/Pagecolumn5

892128-60-8    1334513-02-8    677-22-5   
((S)-isopropyl2-(((S)-(((2R,3R<SUB>,</SUB>5R)-4,4-difluoro-3-hydroxy-5-(2-oxo-4-(2-propylpentanamido)pyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate) 

[1]Patent:WO2015/134334,2015,A1.Locationinpatent:Paragraph00156;00158

99-66-1   
4-amino-1-(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl-1,2-dihydropyrimidin-2-onehydrochloride 
  892128-60-8 

[1]CurrentPatentAssignee:TNTMEDICALCORP;BLUEVALLEYPHARMACEUTICALLLC;TNTMEDICAL-WO2020/107013,2020,A1Locationinpatent:Page/Pagecolumn23-24

892128-60-8    22838-58-0   
(2R,3R,5R)-3-(2S)-2-(tert-butoxy)carbonylamino-3-methylbutanoyloxy-4,4-difluoro-5-2-oxo-4-(2-propylpentanamido)-1,2-dihydropyrimidin-1-yloxolan-2-ylmethyl(2R)-2-(tert-butoxy)carbonylamino-3-methylbutanoate 

[1]CurrentPatentAssignee:TNTMEDICALCORP;BLUEVALLEYPHARMACEUTICALLLC;TNTMEDICAL-WO2020/107013,2020,A1Locationinpatent:Page/Pagecolumn27

Literature

Title: Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110915

Title: Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine.

Journal: Journal of medicinal chemistry 20091126

Title: Pratt SE, et al. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res. 2013 Mar 1;19(5):1159-68.

Title: Jialei Sun, et al. Drug Repurposing of Pyrimidine Analogs as Potent Antiviral Compounds Against Human Enterovirus A71 Infection With Potential Clinical Applications. Sci Rep. 2020 May 18;10(1):8159.

Title: Francia G, et al. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther. 2012 Mar;11(3):680-9.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 892128-60-8
95058-81-4

95058-81-4

 3768-18-1

3768-18-1

 32909-05-0

32909-05-0

 110522-75-3

110522-75-3

 151823-14-2

151823-14-2

 55726-47-1

55726-47-1
Building Blocks
More >
Tags:892128-60-8 Molecular Formula|892128-60-8 MDL|892128-60-8 SMILES|892128-60-8 Ly2334737